These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 16805331

  • 1. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
    Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, Anthony L.
    J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.
    Anticancer Res; 2006 Jun; 26(3B):2325-8. PubMed ID: 16821610
    [Abstract] [Full Text] [Related]

  • 5. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
    Pai V, Porter K, Ranalli M.
    Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C, Vecht J, Masclee AA.
    Aliment Pharmacol Ther; 2005 Nov 15; 22(10):963-9. PubMed ID: 16268971
    [Abstract] [Full Text] [Related]

  • 7. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug 15; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 8. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315.
    Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA.
    J Natl Cancer Inst; 2010 Apr 21; 102(8):547-56. PubMed ID: 20339140
    [Abstract] [Full Text] [Related]

  • 9. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E, Karaoglu A.
    Oncology; 2006 Apr 21; 71(5-6):354-60. PubMed ID: 17873499
    [Abstract] [Full Text] [Related]

  • 10. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery.
    Gullichsen R.
    Tech Coloproctol; 2006 Dec 21; 10(4):346-9. PubMed ID: 17115310
    [Abstract] [Full Text] [Related]

  • 11. Octreotide in the management of diarrhea induced by graft versus host disease.
    Ippoliti C, Neumann J.
    Oncol Nurs Forum; 1998 Jun 21; 25(5):873-8. PubMed ID: 9644703
    [Abstract] [Full Text] [Related]

  • 12. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH, Gould E.
    Clin Ther; 2009 Feb 21; 31(2):347-59. PubMed ID: 19302907
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
    Arts J, Caenepeel P, Bisschops R, Dewulf D, Holvoet L, Piessevaux H, Bourgeois S, Sifrim D, Janssens J, Tack J.
    Clin Gastroenterol Hepatol; 2009 Apr 21; 7(4):432-7. PubMed ID: 19264574
    [Abstract] [Full Text] [Related]

  • 14. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
    Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A.
    Ann Oncol; 2001 Feb 21; 12(2):227-9. PubMed ID: 11300329
    [Abstract] [Full Text] [Related]

  • 15. Glutamine for chemotherapy induced diarrhea: a meta-analysis.
    Sun J, Wang H, Hu H.
    Asia Pac J Clin Nutr; 2012 Feb 21; 21(3):380-5. PubMed ID: 22705427
    [Abstract] [Full Text] [Related]

  • 16. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug 21; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 17. [Management of chemotherapy induced diarrhea].
    Schultz M, Schölmerich J, Kullmann F.
    Z Gastroenterol; 2004 Jun 21; 42(6):527-38. PubMed ID: 15190449
    [Abstract] [Full Text] [Related]

  • 18. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
    Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE, HECTOR Study Group.
    Hepatology; 2007 Jan 21; 45(1):9-15. PubMed ID: 17187405
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 21; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 20. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    J Pain Symptom Manage; 2005 Dec 21; 30(6):563-9. PubMed ID: 16376743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.